Relmada Therapeutics (RLMD) Competitors $0.67 +0.01 (+1.22%) Closing price 04:00 PM EasternExtended Trading$0.67 +0.00 (+0.07%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RLMD vs. ANRO, ORMP, IVVD, VXRT, CELU, ELUT, BYSI, EXOZ, PMVP, and ADAGShould you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include Alto Neuroscience (ANRO), Oramed Pharmaceuticals (ORMP), Invivyd (IVVD), Vaxart (VXRT), Celularity (CELU), Elutia (ELUT), BeyondSpring (BYSI), eXoZymes (EXOZ), PMV Pharmaceuticals (PMVP), and Adagene (ADAG). These companies are all part of the "pharmaceutical products" industry. Relmada Therapeutics vs. Its Competitors Alto Neuroscience Oramed Pharmaceuticals Invivyd Vaxart Celularity Elutia BeyondSpring eXoZymes PMV Pharmaceuticals Adagene Alto Neuroscience (NYSE:ANRO) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings. Do analysts prefer ANRO or RLMD? Alto Neuroscience currently has a consensus price target of $8.50, suggesting a potential upside of 105.41%. Relmada Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 646.83%. Given Relmada Therapeutics' higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than Alto Neuroscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Relmada Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more volatility & risk, ANRO or RLMD? Alto Neuroscience has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Do institutionals & insiders have more ownership in ANRO or RLMD? 45.2% of Relmada Therapeutics shares are owned by institutional investors. 20.7% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to ANRO or RLMD? In the previous week, Alto Neuroscience had 28 more articles in the media than Relmada Therapeutics. MarketBeat recorded 29 mentions for Alto Neuroscience and 1 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.87 beat Alto Neuroscience's score of -0.02 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Alto Neuroscience Neutral Relmada Therapeutics Very Positive Is ANRO or RLMD more profitable? Alto Neuroscience's return on equity of -44.34% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alto NeuroscienceN/A -44.34% -36.73% Relmada Therapeutics N/A -223.17%-180.41% Which has higher valuation & earnings, ANRO or RLMD? Alto Neuroscience is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlto NeuroscienceN/AN/A-$61.43M-$2.39-1.73Relmada TherapeuticsN/AN/A-$79.98M-$2.22-0.30 SummaryAlto Neuroscience beats Relmada Therapeutics on 7 of the 13 factors compared between the two stocks. Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLMD vs. The Competition Export to ExcelMetricRelmada TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.22M$2.48B$5.74B$9.78BDividend YieldN/A1.67%4.40%4.04%P/E Ratio-0.3022.5330.8326.39Price / SalesN/A506.55382.9086.63Price / CashN/A178.3537.7259.11Price / Book1.396.2910.106.62Net Income-$79.98M$32.94M$3.26B$265.42M7 Day Performance9.31%2.27%3.90%3.58%1 Month Performance3.53%1.06%3.73%0.46%1 Year Performance-75.39%5.65%37.68%19.41% Relmada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLMDRelmada Therapeutics4.6381 of 5 stars$0.67+1.2%$5.00+646.8%-76.4%$22.22MN/A-0.3010Positive NewsANROAlto Neuroscience1.8832 of 5 stars$3.40+8.4%$8.50+149.7%-64.4%$85.02MN/A-1.42N/AHigh Trading VolumeORMPOramed Pharmaceuticals0.9912 of 5 stars$2.08flatN/A-14.2%$84.96M$1.34M-5.9410Positive NewsIVVDInvivyd3.9729 of 5 stars$0.58-18.0%$3.85+563.8%-20.2%$84.82M$25.38M-0.63100News CoverageAnalyst ForecastHigh Trading VolumeVXRTVaxart2.0754 of 5 stars$0.36-0.4%$2.00+448.5%-59.5%$83.47M$47.40M-1.35120CELUCelularity0.6453 of 5 stars$4.15+19.3%$6.00+44.6%+30.6%$83.34M$54.22M-1.57220News CoverageELUTElutia3.7028 of 5 stars$2.02flat$8.00+296.0%-40.0%$83.05M$24.38M-1.91180Gap UpBYSIBeyondSpringN/A$1.85-8.4%N/A-11.1%$81.47M$1.75M0.0080Positive NewsHigh Trading VolumeEXOZeXoZymesN/A$9.76+0.6%N/AN/A$81.36M$70K0.0029Positive NewsGap UpPMVPPMV Pharmaceuticals3.1562 of 5 stars$1.56+2.3%$5.50+253.7%-10.0%$80.55MN/A-0.9950Positive NewsADAGAdagene3.0024 of 5 stars$1.96+16.0%$7.00+257.1%-21.0%$79.61M$100K0.00260High Trading Volume Related Companies and Tools Related Companies Alto Neuroscience Alternatives Oramed Pharmaceuticals Alternatives Invivyd Alternatives Vaxart Alternatives Celularity Alternatives Elutia Alternatives BeyondSpring Alternatives eXoZymes Alternatives PMV Pharmaceuticals Alternatives Adagene Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLMD) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access